Testing a new drug for generalized tonic-clonic seizures in Japan
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new medicine (ONO-2017) for people with a type of epilepsy that causes whole-body seizures. It looks at whether adding this drug to your current seizure medicines can reduce how often those seizures happen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Japanese and at least 12 years old.
- You have been diagnosed with primary generalized tonic-clonic seizures (whole-body seizures) as part of idiopathic generalized epilepsy.
- You have had at least 5 of these seizures in the past 12 weeks.
- You are currently taking 1 to 3 seizure medicines at a fixed dose (no recent changes).
- You have not had a seizure emergency (status epilepticus) in the last 15 months.
- You do not have partial seizures (seizures starting in one area of the brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new seizure medication called ONO-2017 in Japanese children and teenagers (ages 2–17) who have a specific type of seizure called POS that hasn't been controlled by current medicines. The goal is to see if this new drug is safe and helps reduce these seizures.
This trial studies the safety of cenobamate for Japanese people who have partial onset seizures and have already finished a previous study of the same drug. It helps doctors learn more about long-term safety.
This study looks at how well cenobamate works when added to other seizure medications for adults with focal epilepsy. It uses real-world data from medical records to see how people respond to treatment.
This trial tests whether a new seizure medicine (cenobamate) helps people whose seizures are caused by an overactive immune system. You would stay on your current treatments and add cenobamate to see if it reduces seizures.
This trial tests a seizure medicine called cenobamate for people in the ICU who are having frequent seizures or a type of prolonged seizure called status epilepticus. It aims to see if this add-on treatment can help control seizures in this setting.
This study looks at how cenobamate (a medication for seizures) affects healthcare use, like hospital visits or emergency room trips, in people with epilepsy whose seizures were not well-controlled by 2 to 5 other medicines. It is a real-world study, meaning it uses medical records to understand the impact.
Hear when a new Epilepsy, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.